Anavex Life Sciences Corp (AVXL)

[falconer66a]

Because of the MOAs.

Why wouldn't what you say -- that the work the company has done holds promising secrets -- not apply to Annovis's posiphen or Cassava's simufilam or the many other biotech's trialling small-molecule drugs?

Joseph, very important question. Thank you for asking it.

Off course, Annovis and Cassava, like all biotechs, have done extensive behind the scenes, proprietary work on their drugs; things they won't be telling the public. Standard trade secret stuff; just like with Anavex.

So, like Anavex, might Annovis and Cassava have discovered some really fine information about their new drugs or drug candidates that will eventually have broad and favorable applications for even more pathologies, other diseases and conditions? Perhaps, but not likely, for several reasons.

First, compare the list of new drugs and potential pathologies listed in the Anavex pipeline. Beyond blarcamesine, several other sigma-1 activators, which are not merely isomers or slightly tweaked analogues; all separate, new, unique molecules which all bind to the sigma-1 receptor protein and as ligands thereto favorably modulate a wide diversity of downstream processes and conditions. I don't find any of that in the pipelines (if any are published) for the other two biotechs. Simply, their molecules work narrowly and specifically. Well and good (perhaps), but they appear to offer nothing beyond what's being currently targeted by the two companies. Stands to reason that if they had things coming along behind locked lab doors, they'd be dropping hints, as Anavex has done for so long.

In summary, the mechanisms of action (MOAs) of the other companies' drugs are chemically and physiologically confined. Not so with the MOAs of Anavex's sigma-1 receptor agonists. Stands to reason. The sigma-1 receptor is a "chaperone," a molecule that guides, controls, promotes, or modulates a diversity of essential downstream reactions. When sigma-1 receptor biology is operating normally, cells function normally. If sigma-1 receptor function is compromised, especially in the neuron, pathologies develop.